Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humansT J Eberlein, M L Rodrick, A F Massaro, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytesJ V Andrews, D D Schoof, M M Bertagnolli, et al.
Surgical Oncology|April 11, 1992
Secondary cytokine production by lymphoid cells used in cellular immunotherapyD D Schoof, P Hunt, J A Obando, et al.
Cancer Research|September 1, 1988
Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cellsD D Schoof, B A Gramolini, D L Davidson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot studyP S Goedegebuure, L M Douville, H Li, et al.
Cellular Immunology|August 1, 1993
CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cellsD D Schoof, Y Terashima, G E Peoples, et al.
Journal of Toxicology. Clinical Toxicology|January 1, 1987
Repeated hemoperfusion and continuous arteriovenous hemofiltration in a paraquat poisoned patientS M Pond, S C Johnston, D D Schoof, et al.
Archives of Surgery (Chicago, Ill. : 1960)|May 1, 1989
Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancerT J Eberlein, D D Schoof, H R Michie, et al.
Archives of Internal Medicine|December 1, 1988
A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicityT J Eberlein, D D Schoof, S E Jung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 15, 1989
Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cellsD S Silberstein, D D Schoof, M L Rodrick, et al.
Pageof 4